Evogene Ltd. Q2 2026 Earnings Call Summary

Moby Intelligence

Wed, August 19, 2026 at 3:30 PM GMT+3 3 min read

Evogene Ltd. Q2 2026 Earnings Call Summary - Moby

Strategic Transformation and Operational Execution

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management has fundamentally restructured Evogene into a lean, AI-driven organization focused on computational chemistry for pharmaceuticals and crop protection.
The company reduced its headcount from 117 to 38 and lowered its annual cash burn from approximately $20.5 million in 2024 to an expected $8.5 million to $9.5 million in 2026.
Strategic monetization of non-core assets included selling Lavie Bio to ICL for $15.25 million and licensing Biomica's Phase I oncology asset to Lishan Biotech.
The core ChemPass AI platform was significantly upgraded through a Google Cloud partnership, expanding the virtual chemical space from 36 billion to 110 billion molecules.
Operational momentum is evidenced by securing 6 active drug development collaborations, with two programs already successfully completing the Hit Identification stage.
Management is actively opposing a dissident shareholder group's attempt to replace the Board, arguing that such a disruption would jeopardize the current strategic momentum.

Strategic Outlook and Growth Objectives

The company expects further reductions in cash burn in 2027 as it continues to optimize its lean operating model.
Management aims to transition from a computational platform provider to a preclinical trial-stage company, which they view as a major valuation inflection point.
Future revenue growth is expected to be driven by R&D fees from new partnerships and milestone payments as molecules advance through development pipelines.
Strategic focus for the second half of 2026 includes initiating discussions with major pharmaceutical companies and advancing internal crop protection programs toward greenhouse trials.
The company plans to expand investor outreach and IR efforts now that the strategic shift has produced tangible validation results rather than just theoretical plans.

Financial Adjustments and Risk Factors

Second quarter net loss improved by nearly 62% year-over-year to $1.8 million, driven by lower operating expenses and reduced losses from discontinued operations.
The company recorded a $3.8 million financial expense related to a warrant inducement transaction in February 2026, offset by $2.1 million in financing income from warrant revaluation.
Revenues decreased to $0.3 million in Q2 2026, primarily due to the conclusion of the AgPlenus agreement with Bayer in May 2026.
Management highlighted regional geopolitical instability in Israel and the Middle East as a significant ongoing risk factor for operations.

Q&A Session Highlights

Monetization potential of ChemPass AI and strategic partnerships

Management believes Evogene is a leader in small molecule discovery for agriculture and is gaining traction in pharma with 6 active collaborations.
Recent discussions have shifted toward including R&D fees to fund activities, a change from earlier agreements that management expects will boost future revenue.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Timeline for Septoria agricultural program field trials

The program is currently validating molecules at low concentrations in biological assays, with greenhouse trials as the next step before approaching global ag-chemical partners.
The focus on Septoria addresses a high-demand market where existing solutions face significant fungal resistance.

Anticipated entry into clinical trials for EVGR510

Management expects to initiate preclinical trials for the most advanced internal programs in the second half of next year.
Internal programs are moving faster than academic collaborations, with the internal pipeline already progressing to Step 3 (Lead Optimization).

Investor outreach and share price performance strategy

Management acknowledged the need for broader investor exposure and plans to engage with new investment bankers and IR firms following the summer period.
The Chairman emphasized that the lean organizational structure and 75% reduction in headcount were necessary steps to preserve runway while proving the AI platform's value.

Status of the AgPlenus herbicide collaboration with Bayer

The collaboration ended because the target protein was found to be non-essential for killing weeds, despite Evogene successfully identifying molecules that bound to the protein.
Management expects the technical success of the discovery process to lead to new, different project discussions with Bayer in the future.